1
|
Banijamali SMA, Versek C, Babinski K, Kamarthi S, Green-LaRoche D, Sridhar S. Portable Multi-focal Visual Evoked Potential Diagnostics for Multiple Sclerosis/Optic Neuritis patients. medRxiv 2023:2023.12.26.23300405. [PMID: 38234795 PMCID: PMC10793525 DOI: 10.1101/2023.12.26.23300405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2024]
Abstract
Purpose Multiple Sclerosis (MS) is a neuro-inflammatory disease of the Central Nervous System (CNS) in which the body's immune system attacks and destroys myelin sheath that protects nerve fibers and causes disruption in axonal signal transmission. Demyelinating Optic Neuritis (ON) is often a manifestation of MS and involves inflammation of the optic nerve. ON can cause vision loss, pain and discomfort in the eyes, and difficulties in color perception.In this study, we developed NeuroVEP, a portable, wireless diagnostic system that delivers visual stimuli through a smartphone in a headset and measures evoked potentials at the visual cortex from near the O1, Oz, O2, O9 and O10 locations on the scalp (extended 10-20 system) using custom electroencephalography (EEG) electrodes. Methods Each test session is constituted by a short 2.5-minute full-field visual evoked potentials (ffVEP) test, followed by a 12.5-minute multifocal VEP (mfVEP) test. The ffVEP test evaluates the integrity of the visual pathway by analyzing the P1 (also known as P100) component of responses from each eye, while the mfVEP test evaluates 36 individual regions of the visual field for abnormalities. Extensive signal processing, feature extraction methods, and machine learning algorithms were explored for analyzing the mfVEP responses. The results of the ffVEP test for patients were evaluated against normative data collected from a group of subjects with normal vision. Custom visual stimuli with simulated defects were used to validate the mfVEP results which yielded 91% accuracy of classification. Results 20 subjects, 10 controls and 10 with MS and/or ON were tested with the NeuroVEP device and a standard-of-care (SOC) VEP testing device which delivers only ffVEP stimuli. In 91% of the cases, the ffVEP results agreed between NeuroVEP and SOC device. Where available, the NeuroVEP mfVEP results were in good agreement with Humphrey Automated Perimetry visual field analysis. The lesion locations deduced from the mfVEP data were consistent with Magnetic Resonance Imaging (MRI) and Optical Coherence Tomography (OCT) findings. Conclusion This pilot study indicates that NeuroVEP has the potential to be a reliable, portable, and objective diagnostic device for electrophysiology and visual field analysis for neuro-visual disorders.
Collapse
Affiliation(s)
| | | | - Kristen Babinski
- Department of Neurology, Tufts University School of Medicine, Tufts Medical Center, Boston, MA, USA
| | - Sagar Kamarthi
- Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA, USA
| | - Deborah Green-LaRoche
- Department of Neurology, Tufts University School of Medicine, Tufts Medical Center, Boston, MA, USA
| | - Srinivas Sridhar
- Department of Physics, Department of Bioengineering and Department of Chemical Engineering, Northeastern University, Boston, MA 02115, NeuroFieldz Inc, Newton, MA, USA
| |
Collapse
|
2
|
Adigbli D, Yang L, Hammond N, Annane D, Arabi Y, Bilotta F, Bohé J, Brunkhorst FM, Cavalcanti AB, Cook D, Engel C, Green-LaRoche D, He W, Henderson W, Hoedemaekers C, Iapichino G, Kalfon P, Rosa GDL, MacKenzie I, Mélot C, Mitchell I, Oksanen T, Polli F, Preiser JC, Soriano FG, Wang LC, Yuan J, Delaney A, Tanna GLD, Finfer S. Intensive glucose control in critically ill adults: a protocol for a systematic review and individual patient data meta-analysis. Crit Care Sci 2023; 35:345-354. [PMID: 38265316 PMCID: PMC10802778 DOI: 10.5935/2965-2774.20230162-en] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 09/06/2023] [Indexed: 01/25/2024]
Abstract
OBJECTIVE The optimal target for blood glucose concentration in critically ill patients is unclear. We will perform a systematic review and meta-analysis with aggregated and individual patient data from randomized controlled trials, comparing intensive glucose control with liberal glucose control in critically ill adults. DATA SOURCES MEDLINE®, Embase, the Cochrane Central Register of Clinical Trials, and clinical trials registries (World Health Organization, clinical trials.gov). The authors of eligible trials will be invited to provide individual patient data. Published trial-level data from eligible trials that are not at high risk of bias will be included in an aggregated data meta-analysis if individual patient data are not available. METHODS Inclusion criteria: randomized controlled trials that recruited adult patients, targeting a blood glucose of ≤ 120mg/dL (≤ 6.6mmol/L) compared to a higher blood glucose concentration target using intravenous insulin in both groups. Excluded studies: those with an upper limit blood glucose target in the intervention group of > 120mg/dL (> 6.6mmol/L), or where intensive glucose control was only performed in the intraoperative period, and those where loss to follow-up exceeded 10% by hospital discharge. PRIMARY ENDPOINT In-hospital mortality during index hospital admission. Secondary endpoints: mortality and survival at other timepoints, duration of invasive mechanical ventilation, vasoactive agents, and renal replacement therapy. A random effect Bayesian meta-analysis and hierarchical Bayesian models for individual patient data will be used. DISCUSSION This systematic review with aggregate and individual patient data will address the clinical question, 'what is the best blood glucose target for critically ill patients overall?'Protocol version 0.4 - 06/26/2023PROSPERO registration:CRD42021278869.
Collapse
Affiliation(s)
- Derick Adigbli
- Critical Care Division, The George Institute for Global Health -
New South Wales, Australia
| | - Li Yang
- Critical Care Division, The George Institute for Global Health -
New South Wales, Australia
| | - Naomi Hammond
- Critical Care Division, The George Institute for Global Health -
New South Wales, Australia
| | | | - Yaseen Arabi
- Intensive Care Department, Medical Director of Respiratory
Services, King Saud Bin Abdulaziz University for Health Sciences - Riyadh, Saudi
Arabia
| | - Federico Bilotta
- Department of Anesthesiology, Critical Care and Pain Medicine,
Policlinico Umberto I, Sapienza University of Rome - Rome, Italy
| | - Julien Bohé
- Service d’Anesthésie-Réanimation-Médecine
Intensive, Groupement Hospitalier Sud, Hospices Civils de Lyon,
Pierre-Bénite, France
| | - Frank Martin Brunkhorst
- Department of Anaesthesiology and Intensive Care Medicine, Jena
University Hospital - Jena, Germany
| | | | - Deborah Cook
- Critical Care Medicine, St Joseph’s Healthcare Hamilton - Ontario,
Canada
| | - Christoph Engel
- Institute for Medical Informatics, Statistics and Epidemiology,
Leipzig University, Leipzig, Germany
| | | | - Wei He
- Department of Critical Care Medicine, Beijing Tong Ren Hospital,
Capital Medical University - Beijing, China
| | - William Henderson
- VA Emergency Operations Centre, UBC Hospital, University of
British Columbia - Columbia, Canada
| | - Cornelia Hoedemaekers
- Department of Critical Care, Radboud University Nijmegen Medical
Centre -Nijmegen, The Netherlands
| | - Gaetano Iapichino
- Anestesiologia e Rianimazione, Universitá degli Studi di
Milano - Milano, Italy
| | | | - Gisela de La Rosa
- Intensive Care Department, Hospital Pablo Tobon Uribe - Medellin,
Colombia
| | - Iain MacKenzie
- InterSystems Corporation - Cambridge, Mass. , United States
| | | | | | - Tuomas Oksanen
- Department of Anesthesiology and Intensive Care, Helsinki
University Hospital and University of Helsinki - Helsinki, Finland
| | | | | | - Francisco Garcia Soriano
- Department of Critical Care Medicine, Hospital das Clinicas,
Universidade de São Paulo - São Paulo, Brazil
| | - Ling-Cong Wang
- Intensive Care Unit, The First Affiliated Hospital of Zhejiang
Traditional Chinese Medical University - Zhejiang, China
| | - Jiaxiang Yuan
- Department of Laparoscopic Surgery, The First Affiliated Hospital
of Zhengzhou University - Zhengzhou, China
| | - Anthony Delaney
- Critical Care Division, The George Institute for Global Health -
New South Wales, Australia
| | - Gian Luca Di Tanna
- Critical Care Division, The George Institute for Global Health -
New South Wales, Australia
| | - Simon Finfer
- Critical Care Division, The George Institute for Global Health -
New South Wales, Australia
| |
Collapse
|